EP3386536A4 - Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation - Google Patents
Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation Download PDFInfo
- Publication number
- EP3386536A4 EP3386536A4 EP16873755.9A EP16873755A EP3386536A4 EP 3386536 A4 EP3386536 A4 EP 3386536A4 EP 16873755 A EP16873755 A EP 16873755A EP 3386536 A4 EP3386536 A4 EP 3386536A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- methods
- antibody construct
- agonist conjugates
- conjugates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562264260P | 2015-12-07 | 2015-12-07 | |
US15/173,075 US20170158772A1 (en) | 2015-12-07 | 2016-06-03 | Compositions of antibody construct - agonist conjugates and methods of use thereof |
US201662371141P | 2016-08-04 | 2016-08-04 | |
PCT/US2016/065353 WO2017100305A2 (fr) | 2015-12-07 | 2016-12-07 | Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3386536A2 EP3386536A2 (fr) | 2018-10-17 |
EP3386536A4 true EP3386536A4 (fr) | 2019-07-31 |
Family
ID=59013332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16873755.9A Withdrawn EP3386536A4 (fr) | 2015-12-07 | 2016-12-07 | Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3386536A4 (fr) |
CA (1) | CA3007311A1 (fr) |
DE (1) | DE212016000029U1 (fr) |
WO (1) | WO2017100305A2 (fr) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018001814A (es) | 2015-08-13 | 2018-05-07 | Merck Sharp & Dohme | Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon. |
US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
SG10201912074PA (en) | 2016-03-18 | 2020-02-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
SG10202008647TA (en) | 2016-10-04 | 2020-10-29 | Merck Sharp & Dohme | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS |
JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
WO2018144955A1 (fr) * | 2017-02-02 | 2018-08-09 | Silverback Therapeutics, Inc. | Compositions de produit de recombinaison-peptide et leurs méthodes d'utilisation |
AR113224A1 (es) * | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
WO2018208667A1 (fr) | 2017-05-12 | 2018-11-15 | Merck Sharp & Dohme Corp. | Composés dinucléotidiques cycliques en tant qu'agonistes sting |
JP2020529421A (ja) | 2017-08-04 | 2020-10-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | がんの処置のためのPD−1アンタゴニストおよびベンゾ[b]チオフェンSTINGアゴニストの組み合わせ |
WO2019027858A1 (fr) | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | Agonistes benzo[b]thiophène de sting pour le traitement du cancer |
CN107365361B (zh) * | 2017-08-21 | 2020-05-19 | 中国药科大学 | 与pd-l1结合的重复域锚定蛋白及其用途 |
WO2019046500A1 (fr) * | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Dinucléotides cycliques utilisés en tant qu'agents anticancéreux |
KR102651946B1 (ko) * | 2017-08-31 | 2024-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
WO2019051489A1 (fr) * | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
BR112020009126A2 (pt) | 2017-11-10 | 2020-10-20 | Takeda Pharmaceutical Company Limited | compostos do modulador sting e métodos de fabricação e uso |
WO2019125974A1 (fr) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Composés dinucléotidiques cycliques utilisés comme agonistes sting |
EP3505188A1 (fr) | 2017-12-29 | 2019-07-03 | Invivogen | Conjugués de dinucléotide pro-cycliques pour l'induction de la cytokine |
JP7326319B2 (ja) | 2018-04-03 | 2023-08-15 | メルク・シャープ・アンド・ドーム・エルエルシー | Stingアゴニストとしてのベンゾチオフェン類及び関連する化合物 |
WO2019195063A1 (fr) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Composés aza-benzothiophènes utilisés en tant qu'agonistes de sting |
CA3101368A1 (fr) | 2018-05-25 | 2019-11-28 | Incyte Corporation | Composes heterocycliques tricycliques en tant qu'activateurs de sting |
US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
US11008344B2 (en) | 2018-07-31 | 2021-05-18 | Incyte Corporation | Tricyclic heteroaryl compounds as STING activators |
CN112714649B (zh) | 2018-09-06 | 2024-07-02 | 第一三共株式会社 | 环状二核苷酸衍生物及其抗体药物偶联物 |
US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
WO2020190725A1 (fr) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugués ciblant le her2 |
MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
AU2020267486A1 (en) | 2019-05-09 | 2021-11-11 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as STING modulators |
AU2020286523A1 (en) * | 2019-06-03 | 2022-02-03 | The University Of Chicago | Methods and compositions for treating cancer with cancer-targeted adjuvants |
EP3980057A1 (fr) | 2019-06-04 | 2022-04-13 | Institut Curie | Méthodes de production de monomères et d'oligomères de la sous-unité b de la toxine de shiga (stxb), et leurs utilisations |
TW202116358A (zh) | 2019-07-19 | 2021-05-01 | 美商免疫感應治療公司 | 抗體-干擾素基因刺激蛋白(sting)促效劑結合物及其於免疫療法之用途 |
US11155567B2 (en) | 2019-08-02 | 2021-10-26 | Mersana Therapeutics, Inc. | Sting agonist compounds and methods of use |
US20220313835A1 (en) * | 2019-09-03 | 2022-10-06 | Bolt Biotherapeutics, Inc. | Aminoquinoline compounds, immunoconjugates, and uses thereof |
WO2021110987A1 (fr) | 2019-12-06 | 2021-06-10 | Life & Soft | Procédés et appareils permettant de diagnostiquer un cancer à partir d'acides nucléiques acellulaires |
CN111233850B (zh) * | 2020-01-21 | 2022-09-23 | 南开大学 | 含苯并噻唑氨基和杂芳基的萘酚衍生物与制备方法和用途 |
EP4106819A1 (fr) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Conjugués d'anticorps de nectine-4 et leurs utilisations |
CN115209921A (zh) | 2020-03-06 | 2022-10-18 | 第一三共株式会社 | 包含新型环状二核苷酸衍生物的抗体药物偶联物 |
EP4117790A1 (fr) | 2020-03-13 | 2023-01-18 | Hephaistos-Pharma | Lipopolysaccharides (lps) détoxifiées, lps naturellement non toxiques, et leurs utilisations |
CA3178464A1 (fr) | 2020-05-15 | 2021-11-18 | Immunesensor Therapeutics, Inc. | Polytherapies a agoniste de sting assorties d'inhibiteurs de points de controle immunitaires |
CA3183993A1 (fr) | 2020-07-01 | 2022-01-06 | Peter R. Baum | Conjugues d'anticorps anti-asgr1 et leurs utilisations |
EP3943505A1 (fr) | 2020-07-22 | 2022-01-26 | Encefa | Peptides cd31 de liaison à cd38 et leurs utilisations |
JPWO2022050300A1 (fr) | 2020-09-02 | 2022-03-10 | ||
US20220168330A1 (en) | 2020-11-09 | 2022-06-02 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
EP4255475A1 (fr) | 2020-12-02 | 2023-10-11 | Institut Curie | Protéines de sous-unité b de toxine de shiga (stxb) pfonctionnalisées et leurs conjugués |
EP4297874A1 (fr) | 2021-02-26 | 2024-01-03 | Brenus Pharma | Cellules cancéreuses soumises à de multiples stress non autologues et leurs utilisations pour vacciner contre des cancers et traiter des cancers |
AU2022315305A1 (en) | 2021-07-23 | 2024-02-01 | Immunesensor Therapeutics, Inc. | Sting agonist combination treatments with cytokines |
CA3231944A1 (fr) | 2021-09-16 | 2023-03-23 | Carole GUILLONNEAU | Domaines de liaison anti-cd45rc humaine et leurs utilisations |
WO2023109942A1 (fr) * | 2021-12-17 | 2023-06-22 | Jacobio Pharmaceuticals Co., Ltd. | Constructions lieurs-composés comprenant de nouveaux composés utiles en tant qu'agonistes de sting et leurs utilisations |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015103987A1 (fr) * | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Composés et compositions pour traiter des tumeurs à her2 positif |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL101038A0 (en) * | 1991-02-21 | 1992-11-15 | Gilead Sciences Inc | Agent specific for trombin and its use |
DE69535592T2 (de) | 1994-03-25 | 2008-06-12 | Isotechnika, Inc., Edmonton | Verbesserung der effektivität von arzneimitteln duren deuterierung |
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US8946387B2 (en) * | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
RU2737765C2 (ru) * | 2012-05-04 | 2020-12-02 | Пфайзер Инк. | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин |
-
2016
- 2016-12-07 CA CA3007311A patent/CA3007311A1/fr not_active Abandoned
- 2016-12-07 EP EP16873755.9A patent/EP3386536A4/fr not_active Withdrawn
- 2016-12-07 WO PCT/US2016/065353 patent/WO2017100305A2/fr active Application Filing
- 2016-12-07 DE DE212016000029.2U patent/DE212016000029U1/de not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015103987A1 (fr) * | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Composés et compositions pour traiter des tumeurs à her2 positif |
Non-Patent Citations (2)
Title |
---|
ADAM J. R. GADD ET AL: "Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity", BIOCONJUGATE CHEMISTRY, vol. 26, no. 8, 16 July 2015 (2015-07-16), US, pages 1743 - 1752, XP055455345, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.5b00302 * |
SINGH S.K., LUISI D.L. & PAK R.H.: "Antibody-Drug Conjugates: Design, Formulationand Physicochemical Stability", PHARM. RES., vol. 32, 19 May 2015 (2015-05-19), pages 3541 - 3571, XP002792278 * |
Also Published As
Publication number | Publication date |
---|---|
CA3007311A1 (fr) | 2017-06-15 |
DE212016000029U1 (de) | 2017-07-30 |
WO2017100305A3 (fr) | 2017-07-20 |
EP3386536A2 (fr) | 2018-10-17 |
WO2017100305A2 (fr) | 2017-06-15 |
WO2017100305A8 (fr) | 2017-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3386536A4 (fr) | Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation | |
EP3383430A4 (fr) | Anticorps et leurs méthodes d'utilisation | |
HK1257056A1 (zh) | 抗dll3抗體藥物綴合物以及使用方法 | |
EP3504243A4 (fr) | Anticorps anti-tim-3 et leurs utilisations | |
EP3515478A4 (fr) | Anticorps pour siglec-15 et leurs méthodes d'utilisation | |
EP3280441A4 (fr) | Anticorps anti-sortiline et leurs méthodes d'utilisation | |
EP3383914A4 (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
EP3316909A4 (fr) | Anticorps anti-ntb-a ainsi que compositions et procédés associés | |
EP3397276A4 (fr) | Anticorps et conjugués de ceux-ci | |
EP3177322A4 (fr) | Anticorps anti-trem2 et leurs procédés d'utilisation | |
EP3151830A4 (fr) | Conjugués anticorps anti-her2-maytansine et méthodes d'utilisation de ceux-ci | |
EP3363816A4 (fr) | Anticorps anti-ox40 et son application | |
EP3383917A4 (fr) | Nouveaux anticorps anti-claudine et méthodes d'utilisation | |
EP3283516A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
EP3134121A4 (fr) | Nouveaux anticorps anti-rnf43 et méthodes d'utilisation | |
EP3394098A4 (fr) | Anticorps anti-myostatine et procédés d'utilisation | |
EP3248005A4 (fr) | Nouveaux composés conjugués de glycane et leurs méthodes d'utilisation | |
EP3386986A4 (fr) | Conjugués porphyrine d'or-peg et procédés d'utilisation | |
EP3270965A4 (fr) | Anticorps cd48 et conjugués de ceux-ci | |
EP3341021A4 (fr) | Anticorps anti-alk et leurs procédés d'utilisation | |
EP3294341A4 (fr) | Compositions et procédés de production de conjugués d'anticorps | |
EP3189079A4 (fr) | Nouveaux anticorps anti-mfi2 et méthodes d'utilisation | |
EP3559042A4 (fr) | Anticorps anti-lilrb3 et leurs procédés d'utilisation | |
EP3283493A4 (fr) | Conjugués de texaphyrine-phospholipide et leurs procédés de préparation | |
EP3285805A4 (fr) | Anticorps thérapeutiques et utilisations de ceux-ci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20180706 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190701 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/32 20060101ALI20190624BHEP Ipc: A61K 39/395 20060101ALI20190624BHEP Ipc: A61K 39/39 20060101ALI20190624BHEP Ipc: C07K 16/28 20060101ALI20190624BHEP Ipc: A61K 47/68 20170101ALI20190624BHEP Ipc: A61K 39/00 20060101AFI20190624BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1261040 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20200213 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200624 |